About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Biomarker can Postpone the Onset of Huntington's Disease

by Hannah Joy on January 3, 2018 at 12:30 PM
Font : A-A+

New Biomarker can Postpone the Onset of Huntington's Disease

A new biomarker identified for Huntington's disease (HD) aids in evaluating the effectiveness of the treatment and can also postpone the onset of the disease, reveals a new study.

The study, led by researchers at Boston University School of Medicine (BUSM) in collaboration with the PREDICT-HD study coordinated by colleagues at the University of Iowa Carver College of Medicine, appears in the journal Neurology.

Advertisement


HD is a fatal, inherited neurological disease that usually manifests between 30 and 50 years of age. The disease is caused by a genetic defect that is passed from parent to child in the Huntington gene. Having too many repeated elements in the gene sequence causes the disease and an increasing number of repeats leads to earlier onset and increased severity of the condition.

The research team studied cerebrospinal fluid (CSF) from 30 individuals who carry the mutation that causes HD, but who were not yet showing symptoms. They were able to identify altered levels of a molecule (also called microRNA) in individuals as much as twenty years before the expected onset of symptoms.
Advertisement

"The most interesting finding was that the levels of the microRNAs begin to increase many years before the individual shows symptoms and continue to increase as disease onset approaches. Clinical trials for new HD treatments that may reduce the levels of the microRNAs suggest that these treatments may postpone the onset of the disease," explained corresponding author Richard H. Myers, PhD, professor of neurology and Director of the Genome Science Institute at BUSM.

According to the researchers these findings may represent a more effective way to tell whether or not HD treatments may postpone the disease before it begins.

"By evaluating microRNAs in the CSF, it may become feasible to perform these trials in people who are HD gene carriers, but who do not yet show symptoms, by giving evidence for which trials may postpone onset and provide more healthy years of life," added Myers.

These findings also suggest that other microRNAs may also be important markers of severity for other neurological diseases such as Parkinson's and Alzheimer's.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Printed Temperature Sensors help with Continuous Temperature Monitoring
Health Benefits of Giloy
Breast Cancer Awareness Month 2021 - It's time to RISE
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.


Recommended Reading
Drug Deutetrabenazine Helps Control Sudden Movements of Huntington Disease
To control a prominent symptom of Huntington disease, chorea, researchers evaluated the efficacy ......
Mutation in the Huntingtin Gene Leads to Huntington Disease
Huntington disease (HD) is caused by a mutation in the huntingtin gene (htt) and is an incurable ......
Onset of Huntington Disease Predicted by Striatal Brain Volume
Huntington disease (HD) is caused by a defect on chromosome four and is an inherited ......
New Test Helps to Streamline Testing for Huntington Disease
To streamline genetic testing for Huntington Disease (HD), a new test may help by generating ......

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use